Press releases

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, in accordance with the intention announced by the Company through a press release, on June 22, 2026, resolved on a directed issue of a total of 1,120,605 shares (the “Directed Issue”). A number of Nordic, international, institutional and professional investors participated in the Directed Issue, including both new and existing shareholders. Through the Directed Issue, Curasight receives approximately DKK 20 million before transaction costs. The Directed Issue has been carried out pursuant to the authorization from the Company's general meeting to the Board of Directors under article 5.1.2 of the Company’s articles of association. The subscription price in the Directed Issue has been set at DKK 17.80 per share (the “Subscription Price”), through an accelerated bookbuilding procedure carried out by Sedermera Corporate Finance AB (“Sedermera”). Curasight recently reported encouraging interim data from its Phase I uTREAT[®] study. Following these results, the Company has carried out the Directed Issue to strengthen its working capital and support the continued clinical development of uTRACE[®] and uTREAT[®] through the end of H1 2027. In connection with the Directed Issue, the Company has also renegotiated the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender").

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of approximately DKK 18 million through an accelerated book-building procedure (the “Directed Issue”). Curasight recently reported encouraging interim data from its Phase I uTREAT[®] study. Following these results, the Company intends to carry out the Directed Issue intended to strengthen its working capital and support the continued clinical development of uTRACE[®] and uTREAT[®] through the end of H1 2027. In connection with the Directed Issue, the Company also intends to renegotiate the outstanding loan from Fenja Capital II A/S ("Fenja Capital", the "Lender").

The shares will be offered exclusively to qualified investors by way of an accelerated bookbuilding process. The Directed Share Issue will be initiated immediately after publication of this announcement and may be terminated at short notice. The Company has appointed Sedermera Corporate Finance (“Sedermera”) as sole global coordinator and sole bookrunner.

Copenhagen, 8 June 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT[®] in patients with aggressive brain cancer (glioblastoma).

A preliminary readout of the Phase 1 clinical trial with uTREAT[®] in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support:

 

· The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) with local, transient opening of the blood-brain barrier (BBB) using mannitol
· High uptake and retention in tumor
· Biodistribution and dosimetry compatible with the ability to deliver a therapeutically relevant radiation dose to the tumor without reaching dose limits for healthy organs
· The data support continued development of Curasight’s therapeutic program using uTREAT[® ]in aggressive brain cancer

Copenhagen, Denmark, 28 May 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, hereby publishes the interim report Q1 2026. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Copenhagen, 26 April 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that AK 2014 Holding ApS, Krasilnikoff Holding ApS and UK Curacap ApS have merged their holding of shares in Curacap II ApS. This announcement is published in accordance with the applicable major shareholding notification rules of Spotlight Stock Market.

Copenhagen, Denmark, 25 March 2026 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

March 25, 2026

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on Wednesday 25 March 2026 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.

Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) issued a convertible loan note to Fenja Capital II A/S (“Fenja Capital”) on 29 December 2025, with a nominal amount of DKK 25 million. Fenja Capital has now exercised its right to partially convert the convertible loan, whereby a total of 429,363 new ordinary shares has been issued at a conversion price of DKK 9,975 per share, corresponding to a nominal value of approximately DKK 4.3 million. In connection with the conversion, all of the converted shares have been sold by Fenja Capital in a block transaction executed between Fenja Capital and a consortium of long-term investors at a price of DKK 15.75.

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therapy platform  across multiple aggressive solid tumors, hereby publishes the Annual Report 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform  addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.